[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363998-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363998-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cellular-and-molecular-biology-an-advanced-in-vitro-bladder-cancer-model-integrating-bladder-cancer-spheroids-into-a-healthy-human-urothelium-for-preclinical-therapeutic-testing","Cellular and Molecular Biology - An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing","","Despite recent therapy advances, refractory bladder cancer still has limited effective options. The work develops 3D-UHU-TU, a 3D bladder cancer microtissue model that embeds spheroids from low- and high-grade human bladder cancer cell lines (RT112 and T24) into a healthy human urothelium. After histopathology and immunofluorescence characterization, conventional Mitomycin C and a herpes simplex oncolytic virus (oHSV-GFP) are tested using confocal microscopy and cytotoxicity assays. The model supports correct urothelial and cancer markers, shows grade-specific responses to MMC, and demonstrates oHSV-GFP-driven targeting and cytotoxicity largely restricted to tumor spheroids. The model is proposed for evaluating safety and efficacy across bladder cancer grades.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cellular-and-molecular-biology-an-advanced-in-vitro-bladder-cancer-model-integrating-bladder-cancer-spheroids-into-a-healthy-human-urothelium-for-preclinical-therapeutic-testing/363998/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cellular-and-molecular-biology-an-advanced-in-vitro-bladder-cancer-model-integrating-bladder-cancer-spheroids-into-a-healthy-human-urothelium-for-preclinical-therapeutic-testing/363998.png","ImageObject",300,407,{"name":42,"@type":43},"RuangKosong","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What gap in bladder cancer treatment motivates this research?","Question",{"text":63,"@type":64},"Refractory bladder cancer remains an unmet need despite therapy advances, and current outcomes have not improved for decades, especially for patients who do not respond to newer options.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the 3D-UHU-TU model constructed?",{"text":68,"@type":64},"3D-UHU-TU integrates bladder cancer spheroids derived from RT112 (low-grade) and T24 (high-grade) cell lines into a healthy human urothelium, forming a human cell-based microtissue model.",{"name":70,"@type":61,"acceptedAnswer":71},"Which treatments are evaluated in the model and what are the main effects?",{"text":72,"@type":64},"The study tests Mitomycin C and an oncolytic herpes simplex virus (oHSV-GFP). MMC induces damage and increased cleaved caspase 3 with minimal harm to surrounding urothelium, while oHSV-GFP localizes to cancer spheroids and triggers syncytia formation, disaggregation, and cytotoxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363998,1790322436,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nARTICLE OPEN   \nCellular and Molecular Biology  \nAn advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing  \nBenjamin O. Murray 1 ✉ , Jinhui Gao1, Laia Pasquina-Lemonche2, Katherine Swarbrick3, Guy Simpson4, Mark A. Chambers4, Hardev Pandha5, Alex Freeman6 and Jennifer L. Rohn1 ✉  \n© The Author(s) 2026  \n\n|  | BACKGROUND: Despite therapy advances, better solutions for refractory bladder cancer remain an unmet need. Human cell-based models may aid in better treatment translation. We introduce 3D-UHU-TU, a bladder cancer microtissue model which incorporates spheroids derived from low- and high-grade human bladder cancer cell lines (RT112 and T24 respectively) into a healthy human urothelium.\u003Cbr>METHODS: After model characterisation with histopathology and immunoﬂuorescence microscopy, we trialled both the conventional chemotherapeutic Mitomycin C (MMC), and a novel herpes simplex oncolytic virus (oHSV-GFP), each assessed using confocal microscopy and cytotoxicity assays.\u003Cbr>RESULTS: We observed correct expression of E- and N-Cadherin, CK7, CK20, GATA3 and Ki-67, alongside invasion and migration phenotypes. MMC treatment caused cell lysis and nuclear damage in cancer spheroids in both low-and high-grade models, with minimal damage to the surrounding healthy urothelium, and a signiﬁcant increase in cleaved caspase 3 in low-grade models. oHSVGFP co-localised in cancer spheroids and induced syncytia, spheroid disaggregation and cytotoxicity with minimal to no colocalisation or cytotoxicity in the healthy urothelium.\u003Cbr>CONCLUSION: 3D-UHU-TU model is useful for testing both treatment safety and efﬁcacy on different grades of bladder cancer |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| .\u003Cbr>Future use of primary tumour spheroids in place of cell lines may allow a personalised medicine approach. |  |  |\n|  | British Journal of Cancer (2026) 135:697–707; [https://doi.org/10.1038/s41416-026-03476-0](https://doi.org/10.1038/s41416-026-03476-0) |  |\n|  |  |  |\n\nINTRODUCTION  \nBladder cancer is one of the most expensive cancers to treat [1, 2], and cases and deaths continue to rise [3, 4] . Due to its molecularly heterogenous nature with various transcriptional, mutational and lineage signatures [5], tumour type-speciﬁc treatments are limited, and outcomes have not improved for the last four decades [6], lagging behind progress with many other cancers [7] . More recent advances in immunotherapies [8] and antibody-drug conjugates, for example enfortumab vedotin [9], are promising, but not all patients respond to them, and their adverse effects can be limiting. Urothelial carcinomas are described clinically by two stage groupings: non-muscle invasive (NMIBC) and muscle-invasive bladder cancer (MIBC) . NMIBC (clinical stage Tis, Ta and T1) comprises ~75% of cases, further separated into low-, intermediate-, high-and very high risk categories, for which a limited number of treatments can be implemented [10, 11] . The chance of recurrence of high-risk NMIBC ﬁve years after surgical resection is  \n~69.5%, with up to ~22.8% progressing to MIBC [12] . First-line treatment for MIBC includes neoadjuvant chemotherapy followed by radical cystectomy or chemoradiotherapy. The patient impact can be signiﬁcant, with overall survival post-treatment at 49% after 5 years and 36% at 10 years [13], with considerable detriment to quality-of-life [14, 15]. This highlights the importance of developing new therapies and models to evaluate them, especially at the NMIBC stage before progression has occurred [16] .  \nThe most widely used preclinical models for bladder cancer are orthotopic and xenograft murine models. However, working with animals is labour-intensive, ethically challenging, expensive a","cbCaihNvB9DOKpxq","https://ap.wps.com/l/cbCaihNvB9DOKpxq","pdf",5325848,11,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction\n## Clinical burden and treatment gaps\n## Limitations of existing preclinical models\n## Rationale for human-based approaches\n## Prior 3D-UHU model context","[{\"question\":\"What gap in bladder cancer treatment motivates this research?\",\"answer\":\"Refractory bladder cancer remains an unmet need despite therapy advances, and current outcomes have not improved for decades, especially for patients who do not respond to newer options.\"},{\"question\":\"How is the 3D-UHU-TU model constructed?\",\"answer\":\"3D-UHU-TU integrates bladder cancer spheroids derived from RT112 (low-grade) and T24 (high-grade) cell lines into a healthy human urothelium, forming a human cell-based microtissue model.\"},{\"question\":\"Which treatments are evaluated in the model and what are the main effects?\",\"answer\":\"The study tests Mitomycin C and an oncolytic herpes simplex virus (oHSV-GFP). MMC induces damage and increased cleaved caspase 3 with minimal harm to surrounding urothelium, while oHSV-GFP localizes to cancer spheroids and triggers syncytia formation, disaggregation, and cytotoxicity.\"}]","Cellular and Molecular Biology - An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing | PDF",1790154934,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09de078f048c132e1e8601dce92d041c.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e91ceb645ce37335e0745163a039a9f4.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a302cbc9eef7ddd7376d8dbf65bcfaa8.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57cef355bcadfed38237a09e9ba83675.webp",980,1301]